HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marketing In Brief

This article was originally published in The Rose Sheet

Executive Summary

Christian Dior: Firm's Capture R60/80 XP anti-aging skin-care range, available now at Dior beauty counters nationwide, incorporates adult stem cells "able to repair tissue, create new cells and even regenerate an organ" to fill wrinkles and put off the signs of aging, according to the company. The technology "takes effect almost instantly, smoothing over the skin's surface to fill in wrinkles and drive the liposome to the skin's lower layers," Dior says. "One hour after applying the product, wrinkles are visibly reduced, and after six hours, the skin becomes more smooth and taut as cell regeneration is activated," firm claims, noting that within six months of use, as many as 100 million new cells are generated. Capture R60/80 XP comes in a Rich Crème, a Serum and an Eye Crème for $80, $90 and $60, respectively

You may also be interested in...



OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Chart: Weekly Trademark Review -- Nov. 2, 2010

Weekly Trademark Review
UsernamePublicRestriction

Register

RS015137

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel